AR044660A1 - ATORVASTATIN PHARMACEUTICAL COMPOSITIONS - Google Patents

ATORVASTATIN PHARMACEUTICAL COMPOSITIONS

Info

Publication number
AR044660A1
AR044660A1 ARP040102009A ARP040102009A AR044660A1 AR 044660 A1 AR044660 A1 AR 044660A1 AR P040102009 A ARP040102009 A AR P040102009A AR P040102009 A ARP040102009 A AR P040102009A AR 044660 A1 AR044660 A1 AR 044660A1
Authority
AR
Argentina
Prior art keywords
atorvastatin
pharmaceutical composition
pharmaceutical compositions
compositions
pharmaceutically acceptable
Prior art date
Application number
ARP040102009A
Other languages
Spanish (es)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR044660A1 publication Critical patent/AR044660A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica granulada en seco que comprende atorvastatina o una sal farmacéuticamente aceptable de la misma, así como una composición farmacéutica granulada en seco que comprende atorvastatina o una sal farmacéuticamente aceptable de la misma en combinación con al menos otro fármaco activo, los procedimientos para preparar tales composiciones, kits para contener tales composiciones, y un procedimiento para tratar hipercolesterolemia y/o hiperlipidemia, osteoporosis, hiperplasia prostática benigna (BPH) y enfermedad de Alzheimer usando una cantidad terapéuticamente eficaz de la composición farmacéutica.A dry granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, the methods for preparing such compositions, kits to contain such compositions, and a method of treating hypercholesterolemia and / or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical composition.

ARP040102009A 2003-06-12 2004-06-10 ATORVASTATIN PHARMACEUTICAL COMPOSITIONS AR044660A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47791703P 2003-06-12 2003-06-12

Publications (1)

Publication Number Publication Date
AR044660A1 true AR044660A1 (en) 2005-09-21

Family

ID=33551780

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102009A AR044660A1 (en) 2003-06-12 2004-06-10 ATORVASTATIN PHARMACEUTICAL COMPOSITIONS

Country Status (15)

Country Link
EP (1) EP1635788A1 (en)
JP (1) JP2006527259A (en)
KR (1) KR100760112B1 (en)
CN (1) CN1805732A (en)
AR (1) AR044660A1 (en)
AU (1) AU2004246867A1 (en)
BR (1) BRPI0411354A (en)
CA (1) CA2465693A1 (en)
CO (1) CO5640071A2 (en)
MX (1) MXPA05012955A (en)
NO (1) NO20060149L (en)
RU (1) RU2325903C2 (en)
TW (1) TW200503689A (en)
WO (1) WO2004110406A1 (en)
ZA (1) ZA200508204B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515430A (en) * 2004-10-18 2007-06-14 テバ ファーマシューティカル インダストリーズ リミティド Method for preparing amorphous atorvastatin hemi-calcium by dissolving a salt in an organic solvent which is a mixture of alcohol and ketone and / or ester and removing the solvent
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
PT2000137E (en) 2006-03-29 2016-02-17 Kowa Co Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
CN101973922B (en) * 2009-05-27 2013-01-23 天津和美生物技术有限公司 Atorvastatin semi-strontium salt polymorphs as well as preparation and application thereof as HMG-CoA enzyme inhibitor
EP2512455B8 (en) 2009-12-18 2014-07-23 FrieslandCampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
RU2012131051A (en) * 2009-12-22 2014-01-27 Новартис Аг COMPOSITION, INCLUDING AMRA 1H-HINAZOLIN-2,4-DION DIA, ANTAGONISTS IN THE FORM OF TABLETS WITH IMMEDIATE RELEASE AND METHOD FOR PRODUCING THEM
EP2575757A1 (en) 2010-06-03 2013-04-10 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
EA018867B1 (en) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Method of producing pharmaceutical composition and product therefrom
CN104825449A (en) * 2014-02-12 2015-08-12 天津药物研究院 Compound composition containing atorvastatin calcium and amlodipine and preparation method of same
CN107111055B (en) * 2014-09-26 2020-02-21 株式会社藤仓 Optical fiber
RU2591079C2 (en) * 2014-12-10 2016-07-10 Александр Владимирович Диковский Pharmaceutical composition of statins with prebiotic for therapy of hypercholesteremia and hyperlipidemia
CA2987209A1 (en) * 2015-06-10 2016-12-15 Evonik Rohm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
WO2017063581A1 (en) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 Oral preparation for the treatment of cardiovascular diseases and preparation method thereof
CN117835971A (en) 2021-08-25 2024-04-05 巴斯夫欧洲公司 Adjuvant composition for direct compression
CN114674944A (en) * 2022-03-04 2022-06-28 苏州东瑞制药有限公司 Method for detecting related substances of amlodipine besylate and atorvastatin calcium compound preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514798A (en) * 1999-11-17 2003-04-22 テバ ファーマシューティカル インダストリーズ リミティド Polymorphism of atorvastatin calcium
SI20848A (en) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Pharmaceutical formulation containing atorvastatin calcium
EP1372616A4 (en) * 2001-03-27 2004-06-23 Ranbaxy Lab Ltd A stable pharmaceutical composition of pravastatin
JP2003055217A (en) * 2001-08-10 2003-02-26 Taiyo Yakuhin Kogyo Kk Pharmaceutical composition
GB0121436D0 (en) * 2001-09-04 2001-10-24 Pfizer Ltd Biomodulated multiparticulate formulations
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
DE60323536D1 (en) * 2002-12-20 2008-10-23 Pfizer Prod Inc DOSAGE FORM CONTAINING A CETP INHIBITOR AND AN HMG-COA REDUCTASE HEMMER

Also Published As

Publication number Publication date
AU2004246867A1 (en) 2004-12-23
TW200503689A (en) 2005-02-01
RU2005136743A (en) 2006-07-27
MXPA05012955A (en) 2006-02-13
CN1805732A (en) 2006-07-19
ZA200508204B (en) 2007-03-28
KR20060025167A (en) 2006-03-20
BRPI0411354A (en) 2006-07-11
EP1635788A1 (en) 2006-03-22
WO2004110406A1 (en) 2004-12-23
JP2006527259A (en) 2006-11-30
CA2465693A1 (en) 2004-12-12
RU2325903C2 (en) 2008-06-10
NO20060149L (en) 2006-03-06
KR100760112B1 (en) 2007-09-18
CO5640071A2 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
NO20060149L (en) Pharmaceutical compounds of atorvastatin
AR044775A1 (en) ATORVASTATIN PHARMACEUTICAL COMPOSITIONS
DK1346041T3 (en) Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease
ATE360630T1 (en) AZABICYCLIC HETEROCYCLES AS MODULATORS OF THE CANNABINOID RECEPTOR
TR200100931T2 (en) New sustained release oral formulations
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
PE20061091A1 (en) CRYSTALLINE BETA-d FORM OF IVABRANDINE HYDROCHLORIDE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
AR048336A1 (en) HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
NO20061640L (en) Rapid dissolution preparation of a calcium receptor active compound
BR0111206A (en) Arylmethylamine derivatives for use as tryptase inhibitors
TW200510375A (en) New compounds
NO20093464L (en) New drug mixtures based on anti-cholinergically effective compounds and beta-mimetics
NO20060022L (en) Stable compositions of atorvastatin prepared by cotton granulation
SE9802208D0 (en) Novel compounds
AR018162A1 (en) SUBSTITUTED PIRROLS, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION
DE60031686D1 (en) PYRAZINONE, COMPOSITIONS CONTAINING THESE COMPOUNDS
NO20051261L (en) Morphine-6-glukuronidsalt
BR0113165A (en) 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
CO5261595A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A COMBINATION OF SALMETEROL AND IPRATROPIUM
TR200200473T2 (en) Rar selective retinoid agonists.
SE9802209D0 (en) Novel compounds
SE0000303D0 (en) Novel compounds
EA200401100A1 (en) 1α-FTOR-25-HYDROXY-16,23E-DIEN-26,27-BISHOMO-20-EPICHOLOCALTI-SPHEROL AND ITS APPLICATION FOR TREATMENT
PT1337246E (en) UTILIZATION OF 6-DIMETHYLAMINOMETHYL-1-PHENYLCYLOHEXANE COMPOUNDS FOR URINARY INCONTINENCE THERAPY

Legal Events

Date Code Title Description
FB Suspension of granting procedure